Table 3.
ADC drugs approved for solid tumors [49].
| ADC | Manufacturers | Approval Years | Targets | Payloads | Indications |
|---|---|---|---|---|---|
| Kadcyla (adorastuzumab emtansine) |
Roche/Genentech | 2013 | HER2 | DM1 | A single agent for the treatment of HER2-positive metastatic breast cancer (MBC) patients who have previously received trastuzumab and taxane (separately or in combination). Additionally, a single-agent adjuvant therapy for HER2-positive early breast cancer patients. |
| Enhertu (trastuzumab deruxtecan) |
Daichi Sankyo/AstraZeneca | 2019 | HER2 | Exatecan-derivative topoisomerase I inhibitor (DXd) | Adult patients with inoperable or metastatic HER2-positive breast cancer. Adult patients with inoperable or metastatic HER2-low breast cancer. Adult patients with inoperable or metastatic non-small cell lung cancer (NSCLC) harboring an activating HER2 (ERBB2) mutation. Treatment for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. |
| Trodelvy (sacituzumab govitecan) |
Immunomedics/Gi lead | 2020 | Trop-2 | SN-38 Topo 1 inhibitor | Adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior treatments for metastatic disease. |
| Padcev (enfortumab vedotin) |
Seagen/Astellas Pharma | 2019 | Nectin-4 | MMAE | Adult patients with locally advanced or metastatic urothelial carcinoma (UC) who have received prior programmed cell death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor therapy, as well as platinum-containing chemotherapy in the neoadjuvant or adjuvant setting, and have received at least two prior systemic regimens for advanced or metastatic disease. |
| Tivdak (tisotumab vedotin) |
Genmab/Seagen | 2021 | TF-011 | MMAE | Recurrent or metastatic cervical cancer progressing during or after chemotherapy. |
| Elahere (mirvetuximab soravtansine) |
ImmunoGen | 2022 | FOLR1 | Maytansinoid DM4 | Adult patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have previously received 1~3 systemic treatment regimens. |